Compared to patients without MACE and/or MALE, those who experienced this outcome displayed significantly higher levels of both MPO (150.17 vs 98.52 ng/mL, respectively; p = 0.020) and MPO–DNA (0.362 vs 0.256 abs 405–490; p = 0.014) at baseline (Table 2), whereas clinical features including age, PAD staging, comorbidities, and baseline treatment were similar between groups (Supplementary Table S2). The gene discussed is MPO; the disease is peripheral arterial disease.